Paris-based Neovacs SA and Boston-based Stellar Biotechnologies Inc have agreed to form a new company, Neostell SAS, to manufacture and sell conjugated vaccines to third parties worldwide as well as to support Neovacs’ proprietary therapeutic vaccine pipeline.
